Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer

Current Opinion in Immunology

Volumn 24, Issue 2, 2012, Pages 246-251

  Chan, Christopher J ^a,b,c   Andrews, Daniel M ^a,b   Smyth, Mark J ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD226 ANTIGEN; CD96 ANTIGEN; GLYCOPROTEIN; IMMUNOGLOBULIN RECEPTOR; MONOCLONAL ANTIBODY; NECTIN; NECTIN LIKE PROTEIN; PROTEIN CRTAM; PROTEIN TIGIT; PROTEIN TIGIT MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW;

ANIMALS; CELL ADHESION MOLECULES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; MONITORING, IMMUNOLOGIC; NEOPLASMS;

EID: 84859162436     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2012.01.009     Document Type: Review

References (37)

1. Riley J.L., June C.H. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 2005, 105:13-21.
2. Burns G.F., Triglia T., Werkmeister J.A., Begley C.G., Boyd A.W. TLiSA1, a human T lineage-specific activation antigen involved in the differentiation of cytotoxic T lymphocytes and anomalous killer cells from their precursors. J Exp Med 1985, 161:1063-1078.
3. Ralston K.J., Hird S.L., Zhang X., Scott J.L., Jin B., Thorne R.F., Berndt M.C., Boyd A.W., Burns G.F. The LFA-1-associated molecule PTA-1 (CD226) on T cells forms a dynamic molecular complex with protein 4.1G and human discs large. J Biol Chem 2004, 279:33816-33828.
4. Shibuya A., Campbell D., Hannum C., Yssel H., Franz-Bacon K., McClanahan T., Kitamura T., Nicholl J., Sutherland G.R., Lanier L.L., et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 1996, 4:573-581.
5. Pende D., Bottino C., Castriconi R., Cantoni C., Marcenaro S., Rivera P., Spaggiari G.M., Dondero A., Carnemolla B., Reymond N., et al. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol 2005, 42:463-469.
6. Castriconi R., Dondero A., Corrias M.V., Lanino E., Pende D., Moretta L., Bottino C., Moretta A. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 2004, 64:9180-9184.
7. Cho D., Shook D.R., Shimasaki N., Chang Y.H., Fujisaki H., Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 2010, 16:3901-3909.
8. Morgado S., Sanchez-Correa B., Casado J.G., Duran E., Gayoso I., Labella F., Solana R., Tarazona R. NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions. J Innate Immun 2011, 3:365-373.
9. Sanchez-Correa B., Morgado S., Gayoso I., Bergua J.M., Casado J.G., Arcos M.J., Bengochea M.L., Duran E., Solana R., Tarazona R. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother 2011, 60:1195-1205.
10. Bottino C., Castriconi R., Pende D., Rivera P., Nanni M., Carnemolla B., Cantoni C., Grassi J., Marcenaro S., Reymond N., et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003, 198:557-567.
11. Soriani A., Zingoni A., Cerboni C., Iannitto M.L., Ricciardi M.R., Di Gialleonardo V., Cippitelli M., Fionda C., Petrucci M.T., Guarini A., et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009, 113:3503-3511.
12. Gilfillan S., Chan C.J., Cella M., Haynes N.M., Rapaport A.S., Boles K.S., Andrews D.M., Smyth M.J., Colonna M. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008, 205:2965-2973.
13. Chan C.J., Andrews D.M., McLaughlin N.M., Yagita H., Gilfillan S., Colonna M., Smyth M.J. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol 2010, 184:902-911.
14. Lakshmikanth T., Burke S., Ali T.H., Kimpfler S., Ursini F., Ruggeri L., Capanni M., Umansky V., Paschen A., Sucker A., et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 2009, 119:1251-1263.
15. Iguchi-Manaka A., Kai H., Yamashita Y., Shibata K., Tahara-Hanaoka S., Honda S., Yasui T., Kikutani H., Shibuya K., Shibuya A. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 2008, 205:2959-2964.
16. Guerra N., Tan Y.X., Joncker N.T., Choy A., Gallardo F., Xiong N., Knoblaugh S., Cado D., Greenberg N.M., Raulet D.H. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008, 28:571-580.
17. Smyth M.J., Crowe N.Y., Godfrey D.I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001, 13:459-463.
18. Yu X., Harden K., Gonzalez L.C., Francesco M., Chiang E., Irving B., Tom I., Ivelja S., Refino C.J., Clark H., et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 2009, 10:48-57.
19. Boles K.S., Vermi W., Facchetti F., Fuchs A., Wilson T.J., Diacovo T.G., Cella M., Colonna M. A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol 2009, 39:695-703.
20. Stanietsky N., Simic H., Arapovic J., Toporik A., Levy O., Novik A., Levine Z., Beiman M., Dassa L., Achdout H., et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A 2009, 106:17858-17863.
21. Levin S.D., Taft D.W., Brandt C.S., Bucher C., Howard E.D., Chadwick E.M., Johnston J., Hammond A., Bontadelli K., Ardourel D., et al. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol 2011, 41:902-915.
22. Joller N., Hafler J.P., Brynedal B., Kassam N., Spoerl S., Levin S.D., Sharpe A.H., Kuchroo V.K. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol 2011, 186:1338-1342.
23. Slavik J.M., Hutchcroft J.E., Bierer B.E. CD28/CTLA-4 and CD80/CD86 families: signaling and function. Immunol Res 1999, 19:1-24.
24. Kennedy J., Vicari A.P., Saylor V., Zurawski S.M., Copeland N.G., Gilbert D.J., Jenkins N.A., Zlotnik A. A molecular analysis of NKT cells: identification of a class-I restricted T cell-associated molecule (CRTAM). J Leukoc Biol 2000, 67:725-734.
25. Fuchs A., Colonna M. The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Semin Cancer Biol 2006, 16:359-366.
26. Boles K.S., Barchet W., Diacovo T., Cella M., Colonna M. The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM. Blood 2005, 106:779-786.
27. Galibert L., Diemer G.S., Liu Z., Johnson R.S., Smith J.L., Walzer T., Comeau M.R., Rauch C.T., Wolfson M.F., Sorensen R.A., et al. Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated molecule. J Biol Chem 2005, 280:21955-21964.
28. Arase N., Takeuchi A., Unno M., Hirano S., Yokosuka T., Arase H., Saito T. Heterotypic interaction of CRTAM with Necl2 induces cell adhesion on activated NK cells and CD8+ T cells. Int Immunol 2005, 17:1227-1237.
29. Takeuchi A., Itoh Y., Takumi A., Ishihara C., Arase N., Yokosuka T., Koseki H., Yamasaki S., Takai Y., Miyoshi J., et al. CRTAM confers late-stage activation of CD8+ T cells to regulate retention within lymph node. J Immunol 2009, 183:4220-4228.
30. Yeh J.H., Sidhu S.S., Chan A.C. Regulation of a late phase of T cell polarity and effector functions by Crtam. Cell 2008, 132:846-859.
31. Masuda M., Maruyama T., Ohta T., Ito A., Hayashi T., Tsukasaki K., Kamihira S., Yamaoka S., Hoshino H., Yoshida T., et al. CADM1 interacts with Tiam1 and promotes invasive phenotype of human T-cell leukemia virus type I-transformed cells and adult T-cell leukemia cells. J Biol Chem 2010, 285:15511-15522.
32. Takahashi Y., Iwai M., Kawai T., Arakawa A., Ito T., Sakurai-Yageta M., Ito A., Goto A., Saito M., Kasumi F., et al. Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer. Breast Cancer 2011.
33. Wang P.L., O'Farrell S., Clayberger C., Krensky A.M. Identification and molecular cloning of tactile. A novel human T cell activation antigen that is a member of the Ig gene superfamily. J Immunol 1992, 148:2600-2608.
34. Fuchs A., Cella M., Giurisato E., Shaw A.S., Colonna M. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol 2004, 172:3994-3998.
35. Seth S., Maier M.K., Qiu Q., Ravens I., Kremmer E., Forster R., Bernhardt G. The murine pan T cell marker CD96 is an adhesion receptor for CD155 and nectin-1. Biochem Biophys Res Commun 2007, 364:959-965.
36. Hosen N., Park C.Y., Tatsumi N., Oji Y., Sugiyama H., Gramatzki M., Krensky A.M., Weissman I.L. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A 2007, 104:11008-11013.
37. Kaname T., Yanagi K., Chinen Y., Makita Y., Okamoto N., Maehara H., Owan I., Kanaya F., Kubota Y., Oike Y., et al. Mutations in CD96, a member of the immunoglobulin superfamily, cause a form of the C (Opitz trigonocephaly) syndrome. Am J Hum Genet 2007, 81:835-841.